Baseline patient demographic information
| Clear fluid diet (n=109) | Low-residue breakfast (n=105) | p Value | |
|---|---|---|---|
| Male sex, % (n) | 45 (49) | 41 (43) | 0.554 |
| Age, median (IQR) | 65 (54–74) | 62 (52–73) | 0.366 |
| Indication for colonoscopy, % (n) | |||
| GI symptoms | 66.9 (71) | 60.0 (63) | 0.777 |
| CRC screening | 19.8 (21) | 18.1 (19) | |
| CRC surveillance | 16.0 (17) | 21.9 (23) | |
| Split-dose preparation, % (n) | 55.1 (60) | 58.6 (61) | 0.595 |
| Completed bowel prep, % (n) | 97.3 (106) | 97.2 (102) | 0.548 |
| Caecal intubation rate, % (n) | 91.7 (100) | 93.3 (98) | 0.505 |
| Polyp detection rate, % (n) | 46.8 (51) | 49.5 (52) | 0.689 |
| Polyp number, median (IQR) | 2 (1–3) | 2 (1–3) | 0.475 |
| Polyp type, % (n) | |||
| Adenoma | 41.1 (21) | 31.4 (16) | 0.518 |
| Advanced adenoma | 37.3 (19) | 39.2 (20) | |
| Non-adenoma | 21.6 (11) | 29.4 (15) | |
| Adenoma detection rate, % (n) | 36.7 (40) | 34.3 (36) | 0.452 |
| Constipating medications, % (n) | 30.3 (33) | 36.2 (38) | 0.358 |
| Previous colonoscopy, % (n) | 50.5 (55) | 46.2 (49) | 0.531 |
| Previous bowel prep, % (n) | |||
| Colyte | 23.2 (25) | 24 (25) | 0.532 |
| PicoSalax | 11.1 (12) | 5.8 (6) | |
| NaPhos | 2.8 (3) | 4.8 (5) | |
| Citromag | 0 | 1 (1) | |
| Unknown | 13.9 (15) | 10.6 (11) | |
| NA | 49.1 (54) | 53.9 (56) | |
CRC, colorectal cancer; GI, gastrointestinal; Hx, history of; NA: not applicable; NaPhos, sodium phosphate.